Open Access
Subscription Access
Open Access
Subscription Access
The Role of Leukotriene Receptor Antagonist as an add on therapy to β2-Agonists in Acute Asthma
Subscribe/Renew Journal
Objective:This study was designed to determine the role of leukotriene receptor antagonist as an add on therapy to β2-agonists in acute asthma. Methods: A prospective study carried out in ESIC hospital in which the total number of 100 patients were enrolled. The study has two arms, the group A treated with salbutamol alone and the group B treated with salbutamol and montelukast. The symptomatic changes and variation in pulmonary function test (PFT), pulse rate (PR), respiratory rate (RR) were compared between both the group. The data were collected, compiled, analysed with statistical tools (SPSS – Microsoft Version 6). Results: In comparison of force expiratory volume % (FEV1 PRED) between the group A and group B, after 24 hours significant change was noticed in group B. The results of forced expiratory volume/forced vital capacity (FEV1/FVC%) shows a significant difference after 24 hours of the treatment with salbutamol in group A and salbutamol plus leukotriene receptor antagonist (Montelukast) from the baseline measurement. Base line asthma score shows p value (p = 0.58). But after 48 hours, significant change was noticed in both groups. p value was significant (p = 0.05). In group B, asthma score was significantly improved with passage of time. Conclusion: The study revealed the effectiveness of leukotriene receptor antagonist in preventing many types of aggravated asthmatic responses. Once-daily treatment with 10 mg of montelukast, as compared with β2-agonists, provided significant protection against severe broncho-constriction. Parameters strongly confirmed the role of leukotriene receptor antagonist when in addition added with β2-agonists.
Keywords
Leukotriene Receptor Antagonist, Acute Asthma, β2-Agonists.
Subscription
Login to verify subscription
User
Font Size
Information
- NHLBI Guideline 2007, pp. 11–12
- "Asthma Fact sheet N°307". WHO. November 2013. Archived from the original on June 29, 2011. Retrieved 3 March 2016. "Asthma Fact sheet N°307". WHO. November 2013. Archived from the original on June 29, 2011. Retrieved 3 March 2016.
- Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I., Zhang, J. and Reiss, T.F. (1999). Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 160: 1862- 1868.
- Tan TA, Spector SL. Exercise-induced asthma: diagnosis and management. Ann Allergy Asthma Immunol 2002;89:226–36.
- Inman MD, O’Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996;153:65–9.
- Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern 2000;132:97–104.
- Kanniess, F., Richter, K., Böhme, S., Jörres, R.A. and Magnussen, H. (2002). Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J. 20: 853-858.
- National Asthma Education and Prevention Program. (1997). Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health. NIH Publication 97-4051.
- Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I., Zhang, J. and Reiss, T.F. (1999). Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 160: 1862-1868.
- Gauvreau, G,M., Parameswaran, K. N., Watson, R.M. and O'Byrne, P.M. (2001) Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med. 164: 1495-1500.
- Barnes, N.C. (2000). Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med. 161: S73-S76.
- Yoshida, S., Ishizaki, Y., Shoji, T., Onuma, K., Nakagawa, H., Nakabayashi, M., Akahori, K., Hasegawa, H. and Amayasu, H. (2000). Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy. 30: 1008-1014.
- Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet L-P, Wei LX, Efthimiadis AE, Zhang J and Hargreave FE (1999). Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. EurRespir J., 14: 12-18.
- Syed hyderrazanaqvi, Mahayrukh, Farooqalamsiddiqui and asif bin rehman (2011). Role of leukotriene receptor antagonist in acute Severe attack of bronchial asthma in comparison with conventional therapy: Pakistan Journal of Pharmacology.,Vol.28, No.2, July 2011, pp.13-21.
- Carlos A. Camargo, Jr., Howard A. Smithline, Marie-Pierre Malice, Stuart A. Green, and Theodore F. Reiss (2003).A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma.Am J RespirCrit Care Med Vol 167. pp 528–533, 2003
- Malmstrom, K., Rodriguez-Gomez, G.and Guerra, J. (1999). Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial; Montelukast/Beclomethasone Study Group. Ann Intern Med. 130: 487-495.
- P. Geetha, M. Kousalya, S. Geetha Lakshmi, R. Gopi. Prescribing Pattern of Drugs Used For Respiratory Disease in Pediatric Patients at Private Hospital. Research J. Pharm. and Tech. 9(3): Mar., 2016; Page 251-256.
- A. Ramya, P. Geetha, P. Shanmugasundaram. Assessment of Appropriate use of Antibiotics in Paediatric Department of A Tertiary Care Teaching Hospital. Research J. Pharm. and Tech. 2017; 10(2): 381-384.
- Pavithra H. Dave, Preetha. Pathogenesis and Novel Drug for Treatment of Asthma – A Review. Research J. Pharm. and Tech 2016; 9(9):1519-1523.
Abstract Views: 229
PDF Views: 0